lansoprazole has been researched along with Coronary Disease in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghebremariam, YT | 1 |
| Cooke, JP | 1 |
| Khan, F | 1 |
| Thakker, RN | 1 |
| Chang, P | 1 |
| Shah, NH | 1 |
| Nead, KT | 1 |
| Leeper, NJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.[NCT02022280] | Phase 1 | 21 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lansoprazole and Coronary Disease
| Article | Year |
|---|---|
Proton pump inhibitors and vascular function: A prospective cross-over pilot study.
Topics: Administration, Oral; Adult; Arginine; Biomarkers; California; Coronary Disease; Cross-Over Studies; | 2015 |